Zihan Yan
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Zihan Yan has a total of 14 co-authors. Here are the top co-authors by number of shared publications:
- Xiaorong Hou
Department of Radiation Oncology, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing, China
3 shared publications - Fuquan Zhang
Department of Radiation Oncology, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China
2 shared publications - Kang Ren
Department of Radiation Oncology, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China
2 shared publications - Wenhui Wang
Department of Radiation Oncology, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China
2 shared publications - Fuquan Zhang
Department of Radiation Oncology Peking Union Medical College Hospital Chinese Academy of Medical Sciences & Peking Union Medical College Beijing P. R. China
1 shared publication - Jiabin Ma
Department of Radiation Oncology, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing, China
1 shared publication
Latest Publications
- Open Access
- 1 January 2026
- Published by XMLink in Journal of Gynecologic Oncology
- Vol. 37 (5)
Annual hazard rates for early-stage endometrial carcinoma after postoperative radiotherapy under FIGO 2023 staging system: results from a population-based single-center cohort study
Xin L, et al. J Gynecol Oncol. 2026 ;37:e107. https://doi.org/10.3802/jgo.2026.37.e107
- 1 January 2026
- Published by XMLink in Journal of Gynecologic Oncology
- Vol. 37 (5)
Open AccessAnnual hazard rates for early-stage endometrial carcinoma after postoperative radiotherapy under FIGO 2023 staging system: results from a population-based single-center cohort study
Xin L, et al. J Gynecol Oncol. 2026 ;37:e107. https://doi.org/10.3802/jgo.2026.37.e107
- Open Access
- 1 January 2026
- Published by XMLink in Journal of Gynecologic Oncology
- Vol. 37 (1)
Timing of adjuvant radiotherapy for early-stage endometrial carcinoma: a single-center retrospective cohort study
Yan Z, et al. J Gynecol Oncol. 2025 Aug;37:e14. https://doi.org/10.3802/jgo.2026.37.e14
- 1 January 2026
- Published by XMLink in Journal of Gynecologic Oncology
- Vol. 37 (1)
Open AccessTiming of adjuvant radiotherapy for early-stage endometrial carcinoma: a single-center retrospective cohort study
Yan Z, et al. J Gynecol Oncol. 2025 Aug;37:e14. https://doi.org/10.3802/jgo.2026.37.e14
- Open Access
- 17 September 2023
- Published by Wiley in Precision Radiation Oncology
- Vol. 7 (3) , 181-188
Clinical outcomes and recurrence patterns of high‐intermediate‐risk and high‐risk early‐stage endometrial cancer treated with postoperative intracavitary brachytherapy
To investigate the clinical outcomes and recurrence patterns of high‐intermediate‐risk (HIR)‐ and high‐risk (HR) early‐stage endometrial cancer (EC) treated with postoperative intracavitary brachytherapy alone. We included 152 patients with International Federation of Gynecology and Obstetrics (FIGO) stage I‐II endometrial cancer with HIR and HR factors who received vaginal brachytherapy alone after surgery in our center between April 2008 and December 2017. The irradiation area was the top and upper halves of the vagina. The reference point was defined as 0.5 cm below the vaginal mucosa. The radiation dose was 25–30 Gy 5–6 times. The Kaplan–Meier method was used to calculate the survival rate; differences were assessed using the log‐rank test, and univariate and multivariate prognostic analyses were performed using the Cox regression model. The median follow‐up was 49.2 months (range 3–132 months). The 5‐year overall survival (OS), disease‐free survival (DFS), locoregional failure‐free survival time (LRFS), and distant metastasis‐free survival (DMFS) rates were 93.2%, 83.4%, 87.9%, and 86.6%, respectively. Treatment failure occurred in 18 patients, locoregional recurrence in 11, and distant metastasis in 14 (four with locoregional recurrence). Distant metastasis is the main recurrence pattern in patients at HIR and HR. Univariate and multivariate analyses revealed that age was an independent prognostic factor for OS, DFS, DMFS, and LRFS. The main recurrence pattern after adjuvant vaginal brachytherapy alone was distant metastasis in patients with HIR and HR early‐stage EC. Age at onset was an independent prognostic factor for survival. Vaginal brachytherapy alone is an acceptable treatment option for patients with HIR and HR early‐stage endometrial cancer.
- 17 September 2023
- Published by Wiley in Precision Radiation Oncology
- Vol. 7 (3) , 181-188
Open AccessClinical outcomes and recurrence patterns of high‐intermediate‐risk and high‐risk early‐stage endometrial cancer treated with postoperative intracavitary brachytherapy
To investigate the clinical outcomes and recurrence patterns of high‐intermediate‐risk (HIR)‐ and high‐risk (HR) early‐stage endometrial cancer (EC) treated with postoperative intracavitary brachytherapy alone. We included 152 patients with International Federation of Gynecology and Obstetrics (FIGO) stage I‐II endometrial cancer with HIR and HR factors who received vaginal brachytherapy alone after surgery in our center between April 2008 and December 2017. The irradiation area was the top and upper halves of the vagina. The reference point was defined as 0.5 cm below the vaginal mucosa. The radiation dose was 25–30 Gy 5–6 times. The Kaplan–Meier method was used to calculate the survival rate; differences were assessed using the log‐rank test, and univariate and multivariate prognostic analyses were performed using the Cox regression model. The median follow‐up was 49.2 months (range 3–132 months). The 5‐year overall survival (OS), disease‐free survival (DFS), locoregional failure‐free survival time (LRFS), and distant metastasis‐free survival (DMFS) rates were 93.2%, 83.4%, 87.9%, and 86.6%, respectively. Treatment failure occurred in 18 patients, locoregional recurrence in 11, and distant metastasis in 14 (four with locoregional recurrence). Distant metastasis is the main recurrence pattern in patients at HIR and HR. Univariate and multivariate analyses revealed that age was an independent prognostic factor for OS, DFS, DMFS, and LRFS. The main recurrence pattern after adjuvant vaginal brachytherapy alone was distant metastasis in patients with HIR and HR early‐stage EC. Age at onset was an independent prognostic factor for survival. Vaginal brachytherapy alone is an acceptable treatment option for patients with HIR and HR early‐stage endometrial cancer.